DARMSTADT, Germany, April 25, 2018 /PRNewswire/ — — Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo — Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a leading science and technology company, today announced the Multiple […]
Vuln!! Path it now!! Vuln!! Path it now!!